Stay updated on SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial
Sign up to get notified when there's something new on the SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial page.

Latest updates to the SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial page
- ChecktodayChange DetectedThe web page has updated its date references, removing older dates from June 2023 and adding new dates in April 2025.SummaryDifference0.6%
- Check7 days agoChange DetectedThe web page has undergone significant updates, including the removal of detailed descriptions of a clinical trial for Head and Neck Squamous Cell Carcinoma (HNSCC) and the addition of a new version revision. Notably, the principal investigator's name and the collaborators have been retained.SummaryDifference53%
- Check15 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check22 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check58 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1.0%
- Check72 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1.0%
Stay in the know with updates to SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial page.